Form 4: Director Stephen Hahn Reports Sensei Biotherapeutics Stock Transactions

Director Stephen M. Hahn reported transactions involving Sensei Biotherapeutics, Inc. common stock and Series B Preferred Stock, alongside stock options.

Summary

• Director Stephen M. Hahn reported a disposition of 44,763 shares of Common Stock on June 15, 2026.
• This disposition is related to a merger agreement dated February 17, 2026, where shares of HoldCo were converted into Series B Preferred Stock.
• The Series B Preferred Stock is convertible into 1,000 shares of Common Stock per share.
• Hahn also acquired a stock option on June 12, 2026, for 25,000 shares of Common Stock at an exercise price of $13.
• This stock option vests over three years, with full vesting by June 12, 2029, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it primarily reports routine insider transactions and a merger-related conversion, without providing new performance data or strategic outlook.

Positives

• Director acquired stock options, indicating potential future equity participation and alignment with company performance.
• The stock option has a clear vesting schedule, incentivizing long-term commitment.

Negatives

• Director disposed of a significant number of common shares (44,763), which could be interpreted as a reduction in direct ownership.

Risks

• The disposition of common stock may signal a reduction in direct beneficial ownership by a key insider.
• The vesting of stock options is contingent on continuous service, introducing employment risk for the director.

Future Outlook

The filing primarily details past transactions and does not contain explicit forward-looking financial guidance. However, the acquisition of stock options with a three-year vesting schedule suggests a long-term outlook by the reporting person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported merger and subsequent stock conversions are common events in the biotechnology sector, often aimed at consolidating or advancing development pipelines.

Stakeholder Impact

• Shareholders: The disposition of shares by a director may be observed, but the acquisition of options suggests continued commitment.
• Employees: The merger details and stock option vesting are standard for executive compensation and retention.

Next Steps

• Continued vesting of stock options over the next three years, contingent on service.
• Potential conversion of Series B Preferred Stock into Common Stock as per its designation.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Merger, Beneficial Ownership, Sensei Biotherapeutics, Stephen Hahn, Series B Preferred Stock, Common Stock